This is a working overview of DMSO stock, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
== History == One of the first LITs was constructed in 1969, by Dierdre A. Church, who bent linear quadrupoles into closed circle and racetrack geometries and demonstrated storage of 3He+ and H+ ions for several minutes. Earlier, Drees and Paul described a circular quadrupole. However, it was used to produce and confine a plasma, not to store ions. In 1989, Prestage, Dick, and Malecki described that ions could be trapped in the linear quadrupole trap system to enhance ion-molecule reactions, thus it can be used to study spectroscopy of stored ions.
== Experimental chemistry == Unambiguous determination of the chemical characteristics of darmstadtium has yet to have been established due to the short half-lives of darmstadtium isotopes and a limited number of likely volatile compounds that could be studied on a very small scale. One of the few darmstadtium compounds that are likely to be sufficiently volatile is darmstadtium hexafluoride (DsF6), as its lighter homologue platinum hexafluoride (PtF6) is volatile above 60 °C and therefore the analogous compound of darmstadtium might also be sufficiently volatile; a volatile octafluoride (DsF8) might also be possible. For chemical studies to be carried out on a transactinide, at least four atoms must be produced, the half-life of the isotope used must be at least 1 second, and the rate of production must be at least one atom per week. Even though the half-life of 281Ds, the most stable confirmed darmstadtium isotope, is 14 seconds, long enough to perform chemical studies, another obstacle is the need to increase the rate of production of darmstadtium isotopes and allow experiments to carry on for weeks or months so that statistically significant results can be obtained. Separation and detection must be carried out continuously to separate out the darmstadtium isotopes and have automated systems experiment on the gas-phase and solution chemistry of darmstadtium, as the yields for heavier elements are predicted to be smaller than those for lighter elements; some of the separation techniques used for bohrium and hassium could be reused.
On 10 November 1952 Thomas's last collection Collected Poems, 1934–1952, was published by Dent; he was 38. It won the Foyle poetry prize. Reviewing the volume, critic Philip Toynbee declared that "Thomas is the greatest living poet in the English language". The winter of 1952/3 brought much personal tragedy: Thomas's father died from pneumonia just before Christmas 1952; and in the Spring of 1953 his sister died from liver cancer, one of his patrons overdosed, three friends died at young ages and Caitlin had an abortion.
== Bibliography == Brock, Sebastian P. (1987). "North Mesopotamia in the late Seventh Century: Book XV of John Bar Penkāyē's Rīš Mellē". Jerusalem Studies in Arabic and Islam. 9: 51–75. ISSN 0334-4118. Crone, Patricia (1980). Slaves on Horses: The Evolution of the Islamic Polity (1980 ed.). Cambridge: Cambridge University Press. p. 93. ISBN 978-0521229616. Donner, Fred M. (2010). Muhammad and the Believers. Cambridge: The Belknap Press of Harvard University Press. ISBN 978-0-674-05097-6. Gibb, H. A. R. (2013) [1923]. The Arab Conquests in Central Asia. Read Books. ISBN 1-4067-5239-8. Gibb, H. A. R. (2007). The Arab Conquests in Central Asia. Read Books. ISBN 978-1-4067-5239-7. reprinted from the 1923 edition, published by the Royal Asiatic Society OCLC 474026895. Hasson, I. (2002). "Ziyād b. Abiḥī". In Bearman, P. J.; Bianquis, Th.; Bosworth, C. E.; van Donzel, E.; Heinrichs, W. P. (eds.). The Encyclopedia of Islam. Vol. XI: W–Z (new ed.). Leiden and New York: Brill. pp. 519–522. ISBN 90-04-12756-9. Kennedy, Hugh (2001). The Armies of the Caliphs: Military and Society in the Early Islamic State. London and New York: Routledge. ISBN 0-415-25093-5. Kennedy, Hugh (2004) [1986]. The Prophet and the Age of the Caliphates: The Islamic Near East from the 6th to the 11th Century (Second ed.). Harlow: Longman. ISBN 978-0-582-40525-7. Madelung, Wifred (October 1981). "ʿAbd Allāh b. al-Zubayr and the Mahdi". Journal of Near Eastern Studies. 4 (1): 291–305. ISSN 0022-2968. JSTOR 544603. Robinson, C. F. (2000). "ʿUbayd Allāh b. Ziyād". In Bearman, P. J.; Bianquis, Th.; Bosworth, C.
Sources: en.wikipedia.org
In November 1949, Pauling, Harvey Itano, S. J. Singer and Ibert Wells published "Sickle Cell Anemia, a Molecular Disease" in the journal Science. It was the first proof of a human disease being caused by an abnormal protein, and sickle cell anemia became the first disease understood at the molecular level. (It was not, however, the first demonstration that variant forms of hemoglobin could be distinguished by electrophoresis, which had been shown several years earlier by Maud Menten and collaborators). Using electrophoresis, they demonstrated that individuals with sickle cell disease have a modified form of hemoglobin in their red blood cells, and that individuals with sickle cell trait have both the normal and abnormal forms of hemoglobin. This was the first demonstration causally linking an abnormal protein to a disease, and also the first demonstration that Mendelian inheritance determines the specific physical properties of proteins, not simply their presence or absence – the dawn of molecular genetics. His success with sickle cell anemia led Pauling to speculate that a number of other diseases, including mental illnesses such as schizophrenia, might result from flawed genetics. As chairman of the Division of Chemistry and Chemical Engineering and director of the Gates and Crellin Chemical Laboratories, he encouraged the hiring of researchers with a chemical-biomedical approach to mental illness, a direction not always popular with established Caltech chemists. In 1951, Pauling gave a lecture entitled "Molecular Medicine".
=== International === By March 2014, Dunkin' Donuts' largest international market was South Korea, representing nearly 40 percent of all international sales. With over 900 outlets in the country, it had three times as many as McDonald's and about a third more than Starbucks. South Korea is home to Dunkin' Donuts' only coffee roasting plant outside the U.S. The company still sees China and its vastly larger population as the more lucrative opportunity. In 2008, Dunkin' Donuts opened its first restaurant in Shanghai, representing the first step in its China expansion strategy. By March 2014, it had about 50 stores in the country and an agreement to open 100 more over the next five years. The operation in China is under a franchise agreement with Jollibee Foods Cooperation, but only seven stores were opened in Beijing, opposed to the planned 100. In 2022, Jollibee announced that it will end the Dunkin Donuts franchise in China to allow expansions into other markets in other regions. Since then, stores started to close and as of 2025, there are no Dunkin stores in mainland China. In Australia, Dunkin' Donuts opened in the 1980s, but by the late 2000s, they had left the Australian market. In 2014, Dunkin' Brands global chairman Nigel Travis said there were no plans in the short term to return the brand to the Australian market. Baskin-Robbins, a subsidiary of Dunkin' Brands, continues to exist in the country. In Brazil, Dunkin' Donuts opened its first building in 1980. In 2013, it planned to open 25 franchises in the country.
Although statistics of the Soviet economy are notoriously unreliable and its economic growth difficult to estimate precisely, by most accounts, the economy continued to expand until the mid-1980s. During the 1950s and 1960s, it had comparatively high growth and was catching up to the West. However, after 1970, the growth, while still positive, steadily declined much more quickly and consistently than in other countries, despite a rapid increase in the capital stock (the rate of capital increase was only surpassed by Japan). Professor of Economic History Bob Allen contends that in the era in which the Soviet economy was publicly owned and planned (1928–1989), the Soviet Union's GDP per capita growth outpaced nearly all other world economies, trailing only Japan, South Korea, and Taiwan. Data shows that Soviet per capita growth expanded by a factor of 5.2, exceeding the growth rates of Western Europe at 4.0, and the US, Canada, Australia, and New Zealand at 3.3. Ultimately, the Soviet model of public ownership proved more effective at raising average incomes during this period than the world's primary industrialized capitalist systems. Scholar Christopher Davidson argued that, during the 1980s, the Reagan administration attempted to weaponize the global energy market against the USSR. At the request of CIA Director William J. Casey, Saudi Arabia flooded the market with oil, dropping the price from $28 to $10 per barrel, and draining Soviet foreign currency reserves. This was later described by a former CIA chief of staff as a "body blow to the Soviets.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.